Prospects for US biotechnology group, Monsanto look set to improve as it continues to gain approval of its genetically modified seeds in key potential markets.

Analyst predict that Monsanto, 85% owned by US drug-maker Pharmacia, will deliver fourth quarter results above expectations, underlying profit in the fourth quarter is close to $US31m. The company has been boosted by sales of its GM Soya bean seeds in the wake of the BSE crisis currently engulfing the world. The lack of soya bean crop has seen many large-scale producers turn to the GM variety to meet demand.

Regulatory moves in a number of countries are also expected to go Monsanto’s way in the next few weeks.

The company expects to gain approval for its genetically modified soya bean seeds in Brazil, while in Japan, Monsanto is awaiting approval of its corn seed. The European Commission is also close to finishing rule changes that would allow Monsanto to start seeking approvals again.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.